Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Country:  U.S.A.
Trial Type:  Prevention
Trial Status:  Active
Results 1-25 of 77 for your search:
Start Over
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 16 to 45
Sponsor: Other
Protocol IDs: P50DA016511, NCT00664755
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Phase: Phase IV
Type: Prevention
Status: Active
Age: 11 to 17
Sponsor: Other
Protocol IDs: GardasilMerckGomez-Lobo, NCT01101750
Smoking Cessation in Hospitalized Smokers
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1U01CA 159533-01, NCT01289275
3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Phase: Phase IV
Type: Prevention
Status: Active
Age: 55 and over
Sponsor: NCI, Other
Protocol IDs: ROI10-352, R01CA138627, NCT01296672
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-0933, NCT01229319
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-0142, NCT02251652
Varenicline and Combined Nicotine Replacement Therapy (NRT) for Smoking Cessation
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2014-0213, NCI-2015-00610, NCT02271919
Impact of Smoking Cessation on Sleep - 5
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NIDA-16427-5, R01-16427-5, DPMC, NCT00132821
New Treatment for Alcohol and Nicotine Dependence
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 15597, 5R01AA019720-02, NCT01182766
Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women
Phase: Phase III
Type: Prevention
Status: Active
Age: 30 to 75
Sponsor: Other
Protocol IDs: GD-10-08, NCT00808522
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Phase: Phase III
Type: Prevention
Status: Active
Age: 26 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113621, NCT01190189
S0820, Adenoma and Second Primary Prevention Trial
Phase: Phase III
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0820, U10CA037429, NCI-2012-02067, NCT01349881
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPP-FAP-310, NCT01483144
An Endometrial Cancer Chemoprevention Study of Metformin
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 50 to 60
Sponsor: NCI, Other
Protocol IDs: 2011-0739, 5P50-CA098258, NCI-2013-00834, NCT01697566
Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Approved-not yet active
Age: 25 to 55
Sponsor: NCI, Other
Protocol IDs: A211102, U10CA031946, NCI-2013-00995, NCT01905046
Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Status: Active
Age: 35 and over
Sponsor: NCI, Other
Protocol IDs: AMC-A01, NCI-2014-00636, U01CA121947, NCT02135419
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Phase: Phase III
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP0108, NCT02137785
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200806, NCT01425476
Changes in Biomarkers Using Prostaglandin Inhibitors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 200807-001, NCT01769625
Exercise Intervention Metabolic Syndrome Prostate Cancer Black Men
Phase: Phase II, Phase I
Type: Prevention
Status: Active
Age: 40 to 70
Sponsor: Other
Protocol IDs: Georgetown_University_MC1, NCT02379559
Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 21 to 70
Sponsor: NCI, Other
Protocol IDs: 2007NT127, R01CA122244, 0712M22651, UMN-2007NT127, PEITC, NCT00691132
Statins and Breast Cancer Biomarkers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 35 to 55
Sponsor: Other
Protocol IDs: V0407, CHRMS#: 05-059, NCT00914017
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Status: Active
Age: 40 to 120
Sponsor: NCI
Protocol IDs: NCI-2009-01192, 09-001758, MC054A, R01-CA-113681, P30CA015083, NCT00983580
Novel Determinants and Measures of Smokeless Tobacco Use: Study 2
Phase: Phase II
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1R01CA141531-01, 1R01CA141531, NCT01067599
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 13 to 26
Sponsor: NCI, Other
Protocol IDs: AMC-072, U01CA121947, CDR0000685816, NCT01209325
Start Over